Terms: = Colorectal cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
134 results:
1. Whole-exome sequencing reveals mutational profiles of anorectal and gynecological melanoma.
Sun W; Liu K; Zhou H; Zhao F; Dong Y; Xu Y; Kong Y; Wang M; Cheng X; Chen Y
Med Oncol; 2023 Oct; 40(11):330. PubMed ID: 37831226
[TBL] [Abstract] [Full Text] [Related]
2. Combined PD-1, braf and MEK inhibition in braf
Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
[TBL] [Abstract] [Full Text] [Related]
3. A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
Robles J; Pintado-Berninches L; Boukich I; Escudero B; de Los Rios V; Bartolomé RA; Jaén M; Martín-Regalado Á; Fernandez-Aceñero MJ; Imbaud JI; Casal JI
J Pathol Clin Res; 2022 Nov; 8(6):495-508. PubMed ID: 36134447
[TBL] [Abstract] [Full Text] [Related]
4. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic colorectal cancer: PLATFORM-B Study.
Vidal J; Fernández-Rodríguez MC; Casadevall D; García-Alfonso P; Páez D; Guix M; Alonso V; Cano MT; Santos C; Durán G; Elez E; Manzano JL; Garcia-Carbonero R; Ferreiro R; Losa F; Pineda E; Sastre J; Rivera F; Bellosillo B; Tabernero J; Aranda E; Salazar R; Montagut C;
Clin Cancer Res; 2023 Jan; 29(2):379-388. PubMed ID: 36074154
[TBL] [Abstract] [Full Text] [Related]
5. Encorafenib plus cetuximab with or without binimetinib in patients with braf V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract] [Full Text] [Related]
6. Genomic Landscape of Primary Tumor Site and clinical outcome for Patients with Metastatic colorectal cancer Receiving Standard-of-Care Chemotherapy.
Mizukami T; Takahashi M; Sunakawa Y; Yuki S; Kagawa Y; Takashima A; Kato K; Hara H; Denda T; Yamamoto Y; Shiozawa M; Oki E; Okamoto W; Yoshino T; Eguchi Nakajima T
Target Oncol; 2022 May; 17(3):343-353. PubMed ID: 35524872
[TBL] [Abstract] [Full Text] [Related]
7. SPATA18 Expression Predicts Favorable clinical outcome in colorectal cancer.
Sugimura-Nagata A; Koshino A; Nagao K; Nagano A; Komura M; Ueki A; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Takahashi S; Kasugai K; Inaguma S
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269894
[TBL] [Abstract] [Full Text] [Related]
8. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer.
Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MHA
Sci Rep; 2022 Feb; 12(1):2767. PubMed ID: 35177765
[TBL] [Abstract] [Full Text] [Related]
9. A five-year follow up study of stage I-IV of rectal cancer with an emphasis on epidermal growth factor over-expression.
Kozłowska-Geller MA; Lewitowicz P; Głuszek SZ
Pol J Pathol; 2021; 72(2):124-129. PubMed ID: 34706519
[TBL] [Abstract] [Full Text] [Related]
10. A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic colorectal cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results.
Wein A; Stoehr R; Kersting S; Siebler J; Merkel S; Busse D; Wolff K; Ostermeier N; Neufert C; Vitali F; Eckstein M; Roth JP; Anhut P; Schreiner W; Uder M; Hartmann A; Neurath MF; Grützmann R
Oncology; 2022; 100(1):1-11. PubMed ID: 34670215
[TBL] [Abstract] [Full Text] [Related]
11. Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer.
Nguyen HG; Lundström O; Blank A; Dawson H; Lugli A; Anisimova M; Zlobec I
Mod Pathol; 2022 Feb; 35(2):240-248. PubMed ID: 34475526
[TBL] [Abstract] [Full Text] [Related]
12. The Role of p53 Expression in Patients with RAS/braf Wild-Type Metastatic colorectal cancer Receiving Irinotecan and Cetuximab as Later Line Treatment.
Ziranu P; Lai E; Schirripa M; Puzzoni M; Persano M; Pretta A; Munari G; Liscia N; Pusceddu V; Loupakis F; Demurtas L; Libertini M; Mariani S; Migliari M; Dubois M; Giampieri R; Sotgiu G; Dei Tos AP; Lonardi S; Zaniboni A; Fassan M; Scartozzi M
Target Oncol; 2021 Jul; 16(4):517-527. PubMed ID: 33970400
[TBL] [Abstract] [Full Text] [Related]
13. Development of braf V600E Mutation in NRAS Q61L Mutated Rectal cancer.
Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL
Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568
[TBL] [Abstract] [Full Text] [Related]
14. Radiomics Texture Features in Advanced colorectal cancer: Correlation with
Negreros-Osuna AA; Parakh A; Corcoran RB; Pourvaziri A; Kambadakone A; Ryan DP; Sahani DV
Radiol Imaging Cancer; 2020 Sep; 2(5):e190084. PubMed ID: 33778733
[TBL] [Abstract] [Full Text] [Related]
15. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
[TBL] [Abstract] [Full Text] [Related]
16. High microsatellite instability (MSI-H) is associated with distinct clinical and molecular characteristics and an improved survival in early Colon cancer (CC); real world data from the AIO molecular registry Colopredict Plus.
Noepel-Duennebacke S; Juette H; Feder IS; Kluxen L; Basara N; Hiller W; Herzog T; Klaassen-Mielke R; Mueller L; Senkal M; Engel L; Teschendorf C; Trenn G; Verdoodt B; Wolters H; Uhl W; Reinacher-Schick A; Tannapfel A
Z Gastroenterol; 2020 Jun; 58(6):533-541. PubMed ID: 32544965
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study.
García-Alfonso P; García-González G; Gallego I; Peligros MI; Ortega L; Torres Pérez-Solero G; Sandoval C; Muñoz Martin A; Blanco Codesido M; Calvo Ferrándiz A; Martin M
Clin Transl Oncol; 2021 Jan; 23(1):122-129. PubMed ID: 32519179
[TBL] [Abstract] [Full Text] [Related]
18. Alterations in signaling pathways that accompany spontaneous transition to malignancy in a mouse model of braf mutant microsatellite stable colorectal cancer.
Kane AM; Fennell LJ; Liu C; Borowsky J; McKeone DM; Bond CE; Kazakoff S; Patch AM; Koufariotis LT; Pearson J; Waddell N; Leggett BA; Whitehall VLJ
Neoplasia; 2020 Feb; 22(2):120-128. PubMed ID: 31935636
[TBL] [Abstract] [Full Text] [Related]
19.
Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
[TBL] [Abstract] [Full Text] [Related]
20. CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor clinical outcome in Stage II colorectal Carcinoma.
Slik K; Turkki R; Carpén O; Kurki S; Korkeila E; Sundström J; Pellinen T
Am J Surg Pathol; 2019 Nov; 43(11):1473-1482. PubMed ID: 31490234
[TBL] [Abstract] [Full Text] [Related]
[Next]
